✦ LIBER ✦

2.290 ONCE YEARLY ZOLEDRONIC ACID IN OSTEOPOROTIC PD PATIENTS COMPARED TO OSTEOPOROTIC POSTMENOPAUSAL WOMEN

✍ Scribed by M. Invernizzi; S. Carda; A. Baricich; C. Cisari

Book ID: 117754982
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 51 KB
Volume: 18
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(11)70613-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Three years of treatment with once-yearl

Three years of treatment with once-yearly zoledronic acid influences the kinetics of bone matrix maturation in osteoporotic patients independent of bone turnover

✍ S. Gamsjaeger; B. Buchinger; J. Gasser; E.F. Eriksen; K. Klaushofer; E.P. Pascha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 65 KB

PMS36 COST-EFFECTIVENESS OF ZOLEDRONIC A

PMS36 COST-EFFECTIVENESS OF ZOLEDRONIC ACID ONCE-YEARLY INFUSION IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROTIC FRACTURES BASED ON COMPLIANCE AND NUMBER NEEDED TO TREAT APPROACH IN THE TURKISH HEALTH CARE SETTING

✍ Pala, M; Göl, D 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

A community-based clinical trial of Intr

A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial: Methodological considerations

✍ Jacques P. Brown; J.D. Adachi; D.L. Kendler; R. Rigal; G. Deutsch; J.M. Leclerc 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Relationship of changes in total hip bon

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

✍ Richard M Jacques; Steven Boonen; Felicia Cosman; Ian R Reid; Douglas C Bauer; D 📂 Article 📅 2012 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 244 KB